Abraxane peak sales?

Abraxane Sales Performance

What are Abraxane's peak sales revenue figures?

Abraxane (paclitaxel protein-bound particles for injectable suspension) is a nanoparticle albumin-bound formulation of paclitaxel developed by American pharmaceutical company Abraxis BioScience, which was later acquired by Celgene in 2010 [1]. Following its approval, Abraxane gained FDA approval for the treatment of metastatic breast cancer in 2005, metastatic pancreatic cancer in 2010, and non-small cell lung cancer in 2013.

Peak Sales Revenue

According to various reports, including a DrugPatentWatch.com study [2], Abraxane reached its peak annual sales revenue in 2014, earning around $1.6 billion for Celgene.

Post-Merger with Bristol Myers Squibb

After Celgene merged with Bristol Myers Squibb in 2019, Abraxane continued to contribute to the combined entity's revenue. However, its sales declined as the market share of generics increased and newer cancer treatments entered the market.

Impact of Generics

The rise of generic formulations has affected Abraxane's sales since 2019, particularly in the European market where generics gained approval in 2020 [3]. The generics' lower pricing put downward pressure on Abraxane's revenue.

Future Outlook

Despite the decrease in sales, Abraxane remains a valuable asset for Bristol Myers Squibb. The company continues to explore its uses, including combination therapies for certain cancer types. However, the long-term future of Abraxane's sales depends on the continued development of more effective and affordable treatments for cancer patients.

References
[1] - https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125333s000lbl.pdf
[2] - DrugPatentWatch.com
[3] - https://www.pharmatimes.com/news/drug-approval-generic-forms-of-albumin-bound-paclitaxel-1232154